The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study ...

Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed. In ...

With the introduction of percutaneous options, the role of surgery in the repair of dysfunctional tricuspid valves is being reevaluated in an effort to reduce the risk for end-stage disease. In the ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S.

The interventional cardiology team at UT Health Tyler announced that they have successfully performed their first procedure using the Abbott TriClip transcatheter edge-to-edge repair system, the first ...

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available medical therapy plus a minimally invasive procedure using a clip to repair ...

CHICAGO -- Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial marking the first report of reduced heart failure (HF) hospitalization ...